Clinical Trial

A Phase II Study of SKB571 in Patients With Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Protocol Amendment History 1 change
notable Enrollment increased: 190 -> 295 participants 2026-05-13
Trial Details
NCT Number NCT07230405
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Lung Cancer (Non-Small Cell)
Enrollment 295 participants
Start Date 2026-01-19
Primary Completion 2028-01-19 (estimated)
Study Completion 2028-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-05-12